ANN ARBOR, Mich., March 3, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today the appointment of George J. Brewer, M.D., as Senior Vice President of Research & Development. Dr. Brewer joins the Adeona management team after serving as the Chairman of the Company's Scientific Advisory Board for seven years.
Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan. He was a member of the National Science Council's "Committee on Copper in Drinking Water" convened at the request of the Environmental Protection Agency in 2000 to consider the issue of what level of copper in drinking water could be considered "safe." Dr. Brewer has published over 500 scientific papers, several books and is the inventor of oral zinc therapy approved by the Food & Drug Administration (FDA) in 1997, now standard of care for chronic Wilson's disease.
"We are pleased that Dr. Brewer, a respected medical innovator and developer of zinc-based therapies over his career, accepted our offer to join Adeona's management team. As the Chairman of our Scientific Advisory Board, Dr. Brewer provided significant guidance with regard to our clinical development programs, and we look forward to his continued valuable contributions in his new role as Senior Vice President of Research & Development," stated James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO. "We also appreciate the condolences received following the passing of our colleague and friend, David Newsome. While this was an unexpected loss for the Company, we believe the appointment of Dr. Brewer positions our clinical development programs for continued advancement."
The study coordinators at the three clinical sites conducting Adeona's study evaluating reaZin™ (zinc cysteine) for the dietary management of Alzheimer's disease and mild cognitive impairment continue the follow-up appointments with the patients enrolled in this study. Adeona has also contracted a replacement clinical trial associate to monitor the study on behalf of the Company. Patients are scheduled to complete their final study visits by the end of March 2011. As previously announced, Adeona plans to present the results of its pivotal clinical trial in a poster presentation at the American Academy of Neurology Annual Meeting on April 14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. A concurrent press release will also be distributed.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical studies and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the availability of financial and other resources and the allocation of resources among different potential uses, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of the new branding to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.